The calcium-binding protein EFhd2 modulates synapse formation in vitro and is linked to human dementia

Journal of Neuropathology and Experimental Neurology

Volumn 73, Issue 12, 2014, Pages 1166-1182

  Borger, Eva ^a   Herrmann, Abigail ^b   Mann, David A ^c   Spires Jones, Tara ^b   Gunn Moore, Frank ^a  

^a UNIVERSITY OF ST ANDREWS   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Alzheimer disease; Cortical neurons; EFhd2; Frontotemporal dementia; Frontotemporal lobar degeneration; Swiprosin 1; Synapses

Indexed keywords

ADAPTOR PROTEIN; CALCIUM BINDING PROTEIN; EF HAND DOMAIN CONTAINING PROTEIN 2; MESSENGER RNA; SHORT HAIRPIN RNA; TAU PROTEIN; UNCLASSIFIED DRUG; EFHD2 PROTEIN, HUMAN;

ADULT; AGED; ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN CELL CULTURE; CLINICAL ARTICLE; CONTROLLED STUDY; DEMENTIA; EMBRYO; FEMALE; FOREBRAIN; FRONTAL CORTEX; FRONTOTEMPORAL DEMENTIA; GENE SILENCING; GROWTH CONE; HUMAN; HUMAN TISSUE; IN VITRO STUDY; MALE; MOUSE; MOUSE EMBRYO; NERVE FIBER GROWTH; NEUROMODULATION; NONHUMAN; PICK PRESENILE DEMENTIA; PROTEIN DEPLETION; PROTEIN EXPRESSION; REDUCTION; SYNAPTOGENESIS; TAUOPATHY; ANIMAL; CELL CULTURE; METABOLISM; PATHOLOGY; PHYSIOLOGY; SYNAPSE;

ANIMALS; CALCIUM-BINDING PROTEINS; CELLS, CULTURED; DEMENTIA; HUMANS; MICE; SYNAPSES;

EID: 84915767481     PISSN: 00223069     EISSN: 15546578     Source Type: Journal    
DOI: 10.1097/NEN.0000000000000138     Document Type: Article

References (48)

1. Crimins JL, Pooler A, Polydoro M, et al. The intersection of amyloid beta and tau in glutamatergic synaptic dysfunction and collapse in Alzheimer's disease. Ageing Res Rev 2013;12:757-63
2. Gong Y, Lippa CF. Review: Disruption of the postsynaptic density in Alzheimer's disease and other neurodegenerative dementias. Am J Alzheimers Dis Other Demen 2010;25:547-55
3. Zhou L, Miller BL, McDaniel CH, et al. Frontotemporal dementia: Neuropil spheroids and presynaptic terminal degeneration. Ann Neurol 1998;44:99-109
4. Scheff SW, Neltner JH, Nelson PT. Is synaptic loss a unique hallmark of Alzheimer's disease? Biochem Pharmacol 2014;88:517-28
5. Goedert M, Ghetti B, Spillantini MG. Frontotemporal dementia: Implications for understanding Alzheimer disease. Cold Spring Harb Perspect Med 2012;2:a006254
6. Ittner LM. Dendritic function of tau mediactes amyloid-b toxicity in Alzheimer's disease mouse models. Cell 2010;142:387-97
7. Shipton OA, Leitz JR, Dworzak J, et al. Tau protein is required for amyloid A-induced impairment of hippocampal long-term potentiation. J Neurosci 2011;31:1688-92
8. Eckermann K, Mocanu MM, Khlistunova I, et al. The beta-propensity of tau determines aggregation and synaptic loss in inducible mouse models of tauopathy. J Biol Chem 2007;282:31755-65
9. Hall GF, Lee VM, Lee G, et al. Staging of neurofibrillary degeneration caused by human tau overexpression in a unique cellular model of human tauopathy. Am J Pathol 2001;158:235-46
10. Bennion Callister J, Pickering-Brown SM. Pathogenesis/genetics of frontotemporal dementia and how it relates to ALS [epub ahead of print June 8, 2014]. Exp Neurol doi: 10.1016/j.expneurol.2014.06.001
11. Ferrer-Acosta Y, Rodríguez-Cruz EN, Orange F, et al. Efhd2 is a novel amyloid protein associated to pathological tau in Alzheimer's disease. J Neurochem 2013;125:921-31
12. Vega IE, Traverso EE, Ferrer-Acosta Y, et al. A novel calcium-binding protein is associated with tau proteins in tauopathy. J Neurochem 2008; 106:96-106
13. Vázquez-Rosa E, Rodríguez-Cruz EN, Serrano S, et al. Cdk5 phosphorylation of EFhd2 at S74 affects its calcium binding activity. Protein Sci 2014;23:1197-207
14. Martins-de-Souza D, Gattaz WF, Schmitt A, et al. Prefrontal cortex shotgun proteome analysis reveals altered calcium homeostasis and immune system imbalance in schizophrenia. Eur Arch Psychiatry Clin Neurosci 2009;259:151-63
15. Kekesi KA, Juhasz G, Simor A, et al. Altered functional protein networks in the prefrontal cortex and amygdala of victims of suicide. PLoS One 2012;7:e50532
16. Zhai J, Strom AL, Kilty R, et al. Proteomic characterization of lipid raft proteins in amyotrophic lateral sclerosis mouse spinal cord. FEBS J 2009; 276:3308-23
17. Kim YD, Kwon MS, Na BR, et al. Swiprosin-1 expression is upregulated through protein kinase C-theta and NF-kappaB pathway in T cells. Immune Netw 2013;13:55-62
18. Thylur RP, Kim YD, Kwon MS, et al. Swiprosin-1 is expressed in mast cells and up-regulated through the protein kinase C beta I/eta pathway. J Cell Biochem 2009;108:705-15
19. Hagen S, Brachs S, Kroczek C, et al. The B-cell receptor-induced calcium flux involves a calcium mediated positive feedback loop. Cell Calcium 2012;51:411-17
20. Kroczek C, Lang C, Brachs S, et al. Swiprosin-1/EFhd2 controls B cell receptor signaling through the assembly of the B cell receptor, Syk, and phospholipase C gamma2 in membrane rafts. J Immunol 2010;184:3665-76
21. Blagoev B, Ong S-E, Kratchmarova I, et al. Temporal analysis of phosphotyrosine-dependent signaling networks by quantitative proteomics. Nat Biotech 2004;22:1139-45
22. Huh YH, Kim SH, Chung KH, et al. Swiprosin-1 modulates actin dynamics by regulating the F-actin accessibility to cofilin. Cell Mol Life Sci 2013;70:4841-54
23. Kwon MS, Park KR, Kim YD, et al. Swiprosin-1 is a novel actin bundling protein that regulates cell spreading and migration. PLoS One 2013; 8:e71626
24. Purohit P, Perez-Branguli F, Prots I, et al. The Ca2+ sensor protein Swiprosin-1/EFhd2 is present in neurites and involved in kinesin-mediated transport in neurons. PLoS One 2014;9:e103976
25. Tai HC, Serrano-Pozo A, Hashimoto T, et al. The synaptic accumulation of hyperphosphorylated tau oligomers in Alzheimer disease is associated with dysfunction of the ubiquitin-proteasome system. Am J Pathol 2012; 181:1426-35
26. Avramidou A, Kroczek C, Lang C, et al. The novel adaptor protein Swiprosin-1 enhances BCR signals and contributes to BCR-induced apoptosis. Cell Death Differ 2007;14:1936-47
27. Vuadens F, Rufer N, Kress A, et al. Identification of swiprosin 1 in human lymphocytes. Proteomics 2004;4:2216-20
28. Hornbruch-Freitag C, Griemert B, Buttgereit D, et al. Drosophila Swiprosin-1/EFHD2 accumulates at the prefusion complex stage during Drosophila myoblast fusion. J Cell Sci 2011;124:3266-78
29. McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7:263-69
30. Andrade-Moraes CH, Oliveira-Pinto AV, Castro-Fonseca E, et al. Cell number changes in Alzheimer's disease relate to dementia, not to plaques and tangles. Brain 2013;136:3738-52
31. Keage HA, Hunter S, Matthews FE, et al. TDP-43 in the population: Prevalence and associations with dementia and age. J Alzheimers Dis 2014;42:641-50
32. Duyckaerts C, Delatour B, Potier MC. Classification and basic pathology of Alzheimer disease. Acta Neuropathol 2009;118:5-36
33. Nordberg A. PET imaging of amyloid in Alzheimer's disease. Lancet Neurol 2004;3:519-27
34. Meng X, Wilkins JA. Compositional characterization of the cytoskeleton of NK-like cells. J Proteome Res 2005;4:2081-87
35. Chen Q, Zhou Z, Zhang L, et al. Tau protein is involved in morphological plasticity in hippocampal neurons in response to BDNF. Neurochem Int 2012;60:233-42
36. Cuesto G, Enriquez-Barreto L, Carames C, et al. Phosphoinositide-3-kinase activation controls synaptogenesis and spinogenesis in hippocampal neurons. J Neurosci 2011;31:2721-33
37. Ramesh TP, Kim YD, Kwon MS, et al. Swiprosin-1 regulates cytokine expression of human mast cell line HMC-1 through actin remodeling. Immune Netw 2009;9:274-84
38. Goto Y, Yang CR, Otani S. Functional and dysfunctional synaptic plasticity in prefrontal cortex: Roles in psychiatric disorders. Biol Psych 2010;67:199-207
39. Blethrow JD, Glavy JS, Morgan DO, et al. Covalent capture of kinasespecific phosphopeptides reveals Cdk1-cyclin B substrates. Proc Natl Acad Sci USA 2008;105:1442-47
40. Mandelkow EM, Biernat J, Drewes G, et al. Tau domains, phosphorylation, and interactions with microtubules. Neurobiol Aging 1995;16:355-62
41. Cole AR, Noble W, van Aalten L, et al. Collapsin response mediator protein-2 hyperphosphorylation is an early event in Alzheimer's disease progression. J Neurochem 2007;103:1132-44
42. Cruz JC, Kim D, Moy LY, et al. p25/Cyclin-dependent kinase 5 induces production and intraneuronal accumulation of amyloid beta in vivo. J Neurosci 2006;26:10536-41
43. Pei J-J, Grundke-Iqbal I, Iqbal K, et al. Accumulation of cyclin-dependent kinase 5 (cdk5) in neurons with early stages of Alzheimer's disease neurofibrillary degeneration. Brain Res 1998;797:267-77
44. Qu D, Rashidian J, Mount MP, et al. Role of Cdk5-mediated phosphorylation of Prx2 in MPTP toxicity and Parkinson's disease. Neuron 2007; 55:37-52
45. Smith PD, Crocker SJ, Jackson-Lewis V, et al. Cyclin-dependent kinase 5 is a mediator of dopaminergic neuron loss in a mouse model of Parkinson's disease. Proc Natl Acad Sci USA 2003;100:13650-55
46. Capsoni S, Brandi R, Arisi I, et al. A dual mechanism linking NGF/proNGF imbalance and early inflammation to Alzheimer's disease neurodegeneration in the AD11 anti-NGF mouse model. CNS Neurol Dis Drug Targ 2011; 10:635-47
47. Holscher C. Diabetes as a risk factor for Alzheimer's disease: Insulin signalling impairment in the brain as an alternative model of Alzheimer's disease. Biochem Soc Trans 2011;39:891-97
48. Schindowski K, Belarbi K, Buee L. Neurotrophic factors in Alzheimer's disease: Role of axonal transport. Genes Brain Behav 2008;7(Suppl 1):43-56